Girisopam
From Wikipedia, the free encyclopedia
Girisopam
|
|
Systematic (IUPAC) name | |
1-(3-chlorophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C18H17ClN2O2 |
Mol. mass | 328.79 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Girisopam (GYKI-51189) is a drug which is a 2,3-benzodiazepine derivative, related to tofisopam. It has selective anxiolytic action with no sedative, anticonvulsant or muscle relaxant effects.[1][2][3]
[edit] References
- ^ Andrási F, Horváth K, Sineger E, Berzsenyi P, Borsy J, Kenessey A, Tarr M, Láng T, Kórösi J, Hámori T. Neuropharmacology of a new psychotropic 2,3-benzodiazepine. Arzneimittelforschung. 1987 Oct;37(10):1119-24.
- ^ Horváth K, Andrási F, Botka P, Hámori T. Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone. Acta Physiologica Hungarica. 1992;79(2):153-61.
- ^ Horváth EJ, Salamon C, Bakonyi A, Fekete MI, Palkovits M. [(3)H]-girisopam, a novel selective benzodiazepine for the 2, 3-benzodiazepine binding site. Brain Research. Brain Research Protocols. 1999 Jul;4(2):230-5.
|